Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProtAffin's its lead product PA401 demonstrated positive result in a preclinical trial, and showed efficacy in gold-standard preclinical models of COPD.
Subscribe to our email newsletter
The company claims that in the trial, the activity of PA401 was benchmarked against other relevant treatment modalities including the PDE4 inhibitor roflumilast and the CXCR2 antagonist SCH527123.
ProtAffin CEO Jason Slingsby they are delighted to announce strong, differentiated efficacy data for our lead product PA401 in preclinical models relevant to COPD.
“We look forward to progressing PA401 through preclinical development in 2010 and 2011 and to starting Phase 1 trials early in 2012. Given the unique properties of PA401 in preclinical models of COPD, PA401 may represent a new treatment paradigm for patients with COPD,” Slingsby said.